This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
cancer: Archive
TEM vs. GH: Which AI in Precision Oncology Stock Has More Upside Now?
by Urmimala Biswas
GH gains ground with stronger guidance, improving margin and Reveal's breakout as TEM scales fast but stays unprofitable.
AZNPositive Net Change GHPositive Net Change TEMNegative Net Change
artificial-intelligence biotechnology cancer earnings-outlook healthcare medical
Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?
by Ekta Bagri
Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.
BMYNegative Net Change PFEPositive Net Change
biotechnology biotechs cancer medical pharmaceuticals
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?
by Sundeep Ganoria
CRSP surges 14% on encouraging CTX310 data and growing Casgevy sales, despite early-stage pipeline risks.
VRTXPositive Net Change BEAMPositive Net Change NTLANegative Net Change CRSPPositive Net Change
biotechs cancer crispr gene-editing gene-therapy healthcare medical
Top Cancer Stocks to Supercharge Your 2025 Portfolio
by Kinjel Shah
Pfizer, Novartis and Fate Therapeutics are making bold oncology moves as demand surges for next-gen cancer therapies.
AZNPositive Net Change NVSPositive Net Change BMYNegative Net Change PFEPositive Net Change LLYPositive Net Change ABBVPositive Net Change FATEPositive Net Change
biotechs cancer pharmaceuticals
Amgen vs Bristol Myers: Which Biotech Giant Has Better Prospects?
by Ekta Bagri
At current levels, we believe AMGN scores above BMY, buoyed by solid fundamentals and recent positive estimate revisions.
BMYNegative Net Change AMGNPositive Net Change
biotechnology biotechs cancer medical pharmaceuticals
Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings
by Sundeep Ganoria
Investors will likely focus on the sales performance of Jazz Pharmaceuticals' key neuroscience drugs, Xywav and Rylaze, when it reports Q1 results next week.
JAZZNegative Net Change AMRXNegative Net Change
biotechs cancer cannabis earnings-preview marijuana medical
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?
by Ekta Bagri
At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV prevention, and recent positive estimate revisions.
BMYNegative Net Change MRKPositive Net Change GILDPositive Net Change
biotechnology biotechs cancer cell-therapy medical pharmaceuticals
Top Cancer Stocks to Buy to Boost Your Portfolio's Health
by Kinjel Shah
If the cancer space appeals to you, it's time to consider stocks like Pyxis Oncology, Verastem Oncology and Relay Therapeutics.
AZNPositive Net Change NVSPositive Net Change PFEPositive Net Change ABBVPositive Net Change VSTMNo Net Change RLAYPositive Net Change PYXSNo Net Change
cancer
Tap Into the Silver Economy Boom With These Aging Demographics Stocks
by Urmimala Biswas
The global demographic shift is reshaping healthcare demand, driving long-term investment in pharmaceuticals, medical devices, home care and digital health.
ABTPositive Net Change NVOPositive Net Change RMDPositive Net Change DXCMPositive Net Change EXASNegative Net Change TNDMNegative Net Change
cancer healthcare hospitals medical medical-devices oncology-screening pharmaceuticals thematic
Recursion Pharma Down 37% in a Month: Buy, Sell or Hold the Stock?
by Ahan Chakraborty
Despite the current downward trend of RXRX, one should retain the stock for long-term gains due to the significant potential of its AI-driven drug discovery technology.
RHHBYNegative Net Change MRKPositive Net Change BAYRYNegative Net Change RXRXPositive Net Change
artificial-intelligence biotechnology biotechs cancer medical oncology-screening pharmaceuticals
Follow the Leader: 2 Biopharma Stocks Showing Relative Strength in 2025
by Bryan Hayes
Despite a correction to begin the year, there are a few pockets of the market that are working.
GILDPositive Net Change JAZZNegative Net Change
biotechnology biotechs cancer cell-therapy earnings immuno-therapy investing medical oncology-screening pharmaceuticals
Pharmaceutical Stocks Hit New Highs Amid Market Volatility
by Bryan Hayes
During this time of heightened market volatility, it pays to be invested in the right places.
GILDPositive Net Change
cancer cell-therapy coronavirus earnings immuno-therapy investing medical oncology-screening vaccines
Hologic Trades at 17.62X P/E: Should You Buy, Sell or Hold the Stock?
by Moumi Mondal
Despite the current challenges, HOLX's portfolio strength and international growth prospects make it worth holding on to.
HOLXPositive Net Change MASIPositive Net Change GMEDPositive Net Change
cancer medical medical-devices
Should You Bet on HOLX Stock This Breast Cancer Awareness Month?
by Moumi Mondal
Hologic has kicked off the annual breast cancer awareness month with a new campaign. But how well is the stock doing now?
ABTPositive Net Change HOLXPositive Net Change QGENPositive Net Change
cancer medical medical-devices
Why Biotech ETFs Are Beating the Market
by Neena Mishra
: Biotech stocks are poised to benefit from lower rates
REGNPositive Net Change GILDPositive Net Change IBBPositive Net Change XBINegative Net Change SBIONegative Net Change
biotechnology biotechs cancer cell-therapy etfs
Zacks Initiates Coverage of Precipio With Outperform Recommendation
by Debanjana Dey
Discover why Zacks rates Precipio as "Outperform", being the first on Wall Street to initiate coverage on the stock. Explore PRPO's approaching breakeven milestones, financial health, and market positioning in the cancer diagnostics space.
PRPOPositive Net Change
cancer medical
Bull of the Day: NVIDIA (NVDA)
by Kevin Cook
After Computex, I raised my price target to $200 because Wall Street still has no idea what's coming
NVDAPositive Net Change
aerospace alt-energy artificial-intelligence automation biotechnology cancer cloud-computing cybersecurity gene-therapy genomics oncology-screening semiconductor smart-health
Moderna (MRNA) Stock Rises 22% YTD: Time to Buy the Stock?
by Sundeep Ganoria
Shares of Moderna (MRNA) continue to soar thanks to the encouraging development of its non-COVID pipeline. The company's potential product launches over the next few years make it worth looking at.
GSKNegative Net Change PFEPositive Net Change MRKPositive Net Change MRNAPositive Net Change
biotechs cancer medical messenger-rna pharmaceuticals vaccines
Top Medical Stocks to Buy for Growth & Performance
by Shaun Pruitt
The medical sector is crawling with opportunity as indicated in its representation on the Zacks Rank #1 (Strong Buy) list.
HAEPositive Net Change HALONegative Net Change NBIXPositive Net Change
cancer earnings hospitals investing medical medical-devices oncology-screening pharmaceuticals
Pfizer (PFE) Stock Falls in a Year: Time to Buy, Sell or Hold?
by Kinjel Shah
Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
BMYNegative Net Change PFEPositive Net Change BNTXNegative Net Change
cancer oncology-screening
Here's Why Eli Lilly (LLY) is Probably the Best Drug Stock Now
by Kinjel Shah
Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.
JNJPositive Net Change PFEPositive Net Change NVOPositive Net Change LLYPositive Net Change
biotechnology cancer gene-therapy
3 Attractive Medical Stocks to Buy After Earnings
by Shaun Pruitt
Following their favorable quarterly results this week here are three intriguing healthcare stocks that investors will want to consider.
MCKPositive Net Change EXELPositive Net Change EHCPositive Net Change
biotechnology cancer earnings hospitals investing medical pharmaceuticals
These Stocks Are Showing Relative Strength as S&P 500 Stalls Near Record High
by Bryan Hayes
As investors, our job isn't to predict an unknowable future.
NVSPositive Net Change LLYPositive Net Change
artificial-intelligence cancer earnings investing large-cap oncology-screening pharmaceuticals semiconductor tech-stocks
Bull of the Day: NeoGenomics (NEO)
by Kevin Cook
Small-cap leader in oncology diagnostics is on sale after patent litigation takes a bite
NEOPositive Net Change NTRAPositive Net Change GHPositive Net Change
cancer genetic-testing genomics oncology-screening smart-health
Bear of the Day: Illumina (ILMN)
by Kevin Cook
Contracting margins, antitrust over GRAIL, and the Icahn invasion all crash estimates and shares
ILMNPositive Net Change
biotechnology cancer genetic-testing genomics oncology-screening smart-health